Skip to main content
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. — Investor Relations & Filings

Ticker · CTKB ISIN · US23285D1090 LEI · 549300K2J28BOC6FBO89 US Manufacturing
Open in API
Filings indexed 412 across all filing types
Latest filing 2022-02-09 Director's Dealing
Country US United States of America
Listing US CTKB

About Cytek Biosciences, Inc.

https://cytekbio.com

Cytek Biosciences, Inc. is a cell analysis solutions company that provides instruments, reagents, and services based on its patented Full Spectrum Profiling (FSP) technology. This technology enables its flow cytometry systems, including the Aurora, Northern Lights, and Muse series, to capture the entire emission spectrum of fluorescent dyes. This allows researchers to conduct high-resolution, high-multiplex experiments, using panels of 40 or more colors from a single sample. By providing more data from precious samples, the technology aims to reduce experimental complexity and cost. Cytek offers a complete solution with its cFluor® reagents, which are optimized for spectral cytometry, alongside software and application support. The company's products are intended to advance biomedical research in fields such as immunology, cancer research, and cell biology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-02-09 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-07 English
FORM 3 SUBMISSION
Director's Dealing
2022-01-06 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 31, 2021, by Cytek Biosciences, Inc. The content focuses on the appointment of a new director, Dr. Vera Imper, to the Board of Directors, including details about the increase in the number of authorized directors, compensation, equity awards, and indemnification agreements. There is no financial data or report content; rather, it is an announcement of a change in the company's board composition. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length (6793 characters) supports it being a detailed announcement rather than a brief notice or a full report. Therefore, the appropriate classification is MANG with high confidence.
2022-01-06 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2021, by Cytek Biosciences, Inc. It announces the issuance of a press release with financial results for the quarter ended September 30, 2021. The document itself does not contain the financial results but rather furnishes the press release as an exhibit. The text explicitly states that the press release is being furnished and that the information is not deemed "filed" for certain regulatory purposes. The document length is 3328 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, a short document announcing the release of financial results or a report is classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR) because it does not contain substantive financial data itself but only references the press release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-11-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.